Business Context and Reporting Period
This Form 8-K filing by Actuate Therapeutics, Inc. (Nasdaq: ACTU) reports on the Company's Annual Meeting of Stockholders held virtually on May 22, 2025. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not reported in this document.
Material Changes
No material financial changes are reported. The filing details the outcome of corporate governance votes:
- Director Elections: Stockholders elected three Class I director nominees (Dr. Roger Sawhney, Mr. Todd Thomson, and Dr. Dan Zabrowski) to serve three-year terms until the 2028 Annual Meeting.
- Auditor Ratification: Stockholders ratified the appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a report of voting results.
Investor Verification Checklist
- Verify the final vote counts for the three Class I director nominees, noting the number of "For" votes versus "Withheld" votes.
- Confirm the ratification of Crowe LLP as the independent auditor for the 2025 fiscal year.
- Note the significant number of broker non-votes (1,045,368) recorded for the director elections.